Biotech · Private company

ADC Therapeutics S.A.

Track this companyFree. Adds ADC Therapeutics S.A. to your Dealase workspace and tells you when its record changes.

Clinical trials2511 recruiting or active

Pipeline programs25From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline25

GemcitabinePhase 3 · Relapsed Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Loncastuximab TesirinePhase 3 · Relapsed Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
OxaliplatinPhase 3 · Relapsed Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 3 · Relapsed Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Camidanlumab TesirinePhase 2 · Relapsed Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
IbrutinibPhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
IdelalisibPhase 2 · Relapsed Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Loncastuximab tesirinePhase 2 · Diffuse Large B-Cell Lymphoma RefractoryClinicalTrials.gov · fetched Nov 12, 2026
Loncastuximab TesirinePhase 2 · Relapsed Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Loncastuximab TesirinePhase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ADCT-301Phase 1 · Head and Neck Cancer Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
ADCT-601Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
ADCT-901Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
DoxorubicinPhase 1 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
GlofitamabPhase 1 · B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Loncastuximab TesirinePhase 1 · B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
MosunetuzumabPhase 1 · B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ObinutuzumabPhase 1 · B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Head and Neck Cancer Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Polatuzumab VedotinPhase 1 · B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
PrednisonePhase 1 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
VincristinePhase 1 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)PHASE1_PHASE2 · RECRUITING · started Nov 5, 2026ClinicalTrials.gov NCT07573436 · fetched Nov 12, 2026
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaPHASE2 · RECRUITING · started Jan 7, 2026ClinicalTrials.gov NCT06919939 · fetched Nov 12, 2026
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)PHASE2 · RECRUITING · started Aug 25, 2025ClinicalTrials.gov NCT06788964 · fetched Nov 12, 2026
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)PHASE1 · RECRUITING · started Mar 18, 2025ClinicalTrials.gov NCT06607549 · fetched Nov 12, 2026
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 18, 2023ClinicalTrials.gov NCT05971251 · fetched Nov 12, 2026
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)PHASE1 · TERMINATED · started Jul 28, 2023ClinicalTrials.gov NCT05660395 · fetched Nov 12, 2026
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started May 24, 2023ClinicalTrials.gov NCT05600686 · fetched Nov 12, 2026
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid TumorsPHASE1 · TERMINATED · started Jul 13, 2022ClinicalTrials.gov NCT05389462 · fetched Nov 12, 2026
Long-term Registry of Patients Treated With Loncastuximab TesirineWITHDRAWN · started Jun 30, 2022ClinicalTrials.gov NCT05160064 · fetched Nov 12, 2026
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)PHASE2 · TERMINATED · started Jun 21, 2022ClinicalTrials.gov NCT05144009 · fetched Nov 12, 2026
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone LymphomaPHASE2 · RECRUITING · started Jun 21, 2022ClinicalTrials.gov NCT05296070 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)PHASE1 · ACTIVE_NOT_RECRUITING · started Jun 17, 2022ClinicalTrials.gov NCT04970901 · fetched Nov 12, 2026
Loncastuximab Tesirine in WMPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 17, 2022ClinicalTrials.gov NCT05190705 · fetched Nov 12, 2026
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaPHASE2 · RECRUITING · started Feb 11, 2022ClinicalTrials.gov NCT04998669 · fetched Nov 12, 2026
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)PHASE1 · WITHDRAWN · started Feb 1, 2022ClinicalTrials.gov NCT04974996 · fetched Nov 12, 2026
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPNPHASE2 · TERMINATED · started Dec 7, 2021ClinicalTrials.gov NCT04639024 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaPHASE2 · TERMINATED · started Nov 4, 2021ClinicalTrials.gov NCT04699461 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid TumorsPHASE1 · COMPLETED · started Sep 9, 2021ClinicalTrials.gov NCT04972981 · fetched Nov 12, 2026
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 16, 2020ClinicalTrials.gov NCT04384484 · fetched Nov 12, 2026
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaPHASE1_PHASE2 · TERMINATED · started Sep 30, 2019ClinicalTrials.gov NCT04082936 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin LymphomaPHASE2 · COMPLETED · started Sep 13, 2019ClinicalTrials.gov NCT04052997 · fetched Nov 12, 2026
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaPHASE1_PHASE2 · TERMINATED · started Dec 1, 2018ClinicalTrials.gov NCT03684694 · fetched Nov 12, 2026
Study of ADCT-301 in Patients With Selected Advanced Solid TumorsPHASE1 · TERMINATED · started Nov 9, 2018ClinicalTrials.gov NCT03621982 · fetched Nov 12, 2026
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaPHASE1_PHASE2 · TERMINATED · started Aug 24, 2018ClinicalTrials.gov NCT03698552 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaPHASE2 · COMPLETED · started Aug 1, 2018ClinicalTrials.gov NCT03589469 · fetched Nov 12, 2026